Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IARS1 | P41252 | 4/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14478983 | 1.00 | IARS1 (0.33) | IARS1F10 | |
| SCHEMBL12355191 | 1.00 | IARS1 (0.33) | IARS1F10 | |
| SCHEMBL6123884 | 0.87 | F10 (0.30) | IARS1F10 | |
| SCHEMBL13692694 | 0.87 | F10 (0.30) | F10 | |
| SCHEMBL12346246 | 0.86 | F10 (0.35) | F10 | |
| SCHEMBL730705 | 0.85 | F10 (0.35) | IARS1F10 | |
| SCHEMBL12892710 | 0.85 | F10 (0.35) | IARS1F10 | |
| SCHEMBL12895304 | 0.85 | F10 (0.35) | IARS1F10 | |
| SCHEMBL403268 | 0.81 | OGA (0.33) | IARS1 | |
| SCHEMBL14478994 | 0.80 | IARS1 (0.33) | IARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355658-A1 | MEDICAL USE OF TAFOXIPARIN | DILAFOR AB (SE) | 2023-11-09 | — | — | US | disclosed |
| US-20230144378-A1 | TAFOXIPARIN FOR THE TREATMENT OF PREECLAMPSIA | DILAFOR AB (SE) | 2023-05-11 | — | — | US | disclosed |
| US-10023659-B2 | Processes for the production of chemically-modified heparins | DILAFOR AB (SE) | 2018-07-17 | — | — | US | disclosed |
| US-10023603-B2 | Preparation of monosaccharides, disaccharides, trisaccharides, and pentasaccharides of heparinoids | FORMOSA LABORATORIES, INC. (TW) | 2018-07-17 | — | — | US | disclosed |
| US-20170015695-A1 | PREPARATION OF MONOSACCHARIDES, DISACCHARIDES, TRISACCHARIDES, AND PENTASACCHARIDES OF HEPARINOIDS | FORMOSA LABORATORIES, INC. (TW) | 2017-01-19 | — | — | US | disclosed |
| US-9480701-B2 | Low anticoagulant heparins | DILAFORETTE AB (SE) | 2016-11-01 | — | — | US | disclosed |
| US-9480702-B2 | Use of chemically modified heparin derivates in sickle cell disease | DILAFORETTE AB (SE) | 2016-11-01 | — | — | US | disclosed |
| US-9475888-B2 | Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use | DILAFOR AB (SE) | 2016-10-25 | — | — | US | disclosed |
| US-20160137754-A1 | NEW PROCESSES FOR THE PRODUCTION OF CHEMICALLY-MODIFIED HEPARINS | DILAFOR AB (SE) | 2016-05-19 | — | — | US | disclosed |
| US-9243018-B2 | Synthetic heparin pentasaccharides | DR. REDDY'S LABORATORIES, SA (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20120220759-A1 | SYNTHETIC HEPARIN DISACCHARIDES | ALCHEMIA LIMITED (AU) | 2012-08-30 | — | — | US | disclosed |
| US-20120208993-A1 | SYNTHETIC HEPARIN TRISACCHARIDES | ALCHEMIA LIMITED (AU) | 2012-08-16 | — | — | US | disclosed |
| US-20120156294-A1 | Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration | NOVO NORDISK A/S (DK) | 2012-06-21 | — | — | US | disclosed |
| US-8114970-B2 | Synthetic heparin monosaccharides | ALCHEMIA LIMITED (AU) | 2012-02-14 | — | — | US | disclosed |
| US-20110236474-A1 | Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration | NOVO NORDISK A/S (DK) | 2011-09-29 | — | — | US | disclosed |
| US-20110201572-A1 | PHARMACEUTICAL COMPOSITION WITH GLYCOSAMINOGLYCANS AND USE THEREOF IN THE TREATMENT OF CHRONIC ULCERS | LABORATORIOS FARMACEUTICOS ROVI, S.A. (ES) | 2011-08-18 | — | — | US | disclosed |
| US-20100239673-A1 | Blood compatible nanomaterials and methods of making and using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-09-23 | — | — | US | disclosed |
| US-7741311-B2 | Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing | MOUSA SHAKER | 2010-06-22 | — | — | US | disclosed |
| US-20090187013-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | ALCHEMIA LIMITED (AU) | 2009-07-23 | — | — | US | disclosed |
| US-7541445-B2 | Synthetic heparin pentasaccharides | ALCHEMIA LIMITED (AU) | 2009-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110236474-A1 | Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration | F12, F13B, F11 | IARS1 4257/4885F10 8/4885 |
| US-20100239673-A1 | Blood compatible nanomaterials and methods of making and using the same | MB, ICAM1, F3 | IARS1 815/4885F10 27/4885 |
| US-10023603-B2 | Preparation of monosaccharides, disaccharides, trisaccharides, and pentasaccharides of heparinoids | HPSE, DDOST, FUT5 | IARS1 2204/4885F10 134/4885 |
| US-10023659-B2 | Processes for the production of chemically-modified heparins | HPSE, F10, FGB | IARS1 2708/4885F10 2/4885 |
| US-20120156294-A1 | Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration | F12, F13B, F11 | IARS1 4004/4885F10 8/4885 |
| US-20230355658-A1 | MEDICAL USE OF TAFOXIPARIN | PGF, PTGIR, PTGFR | IARS1 3591/4885F10 35/4885 |
| US-20090187013-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | HPSE, DDOST, STT3A | IARS1 2572/4885F10 107/4885 |
| US-20170015695-A1 | PREPARATION OF MONOSACCHARIDES, DISACCHARIDES, TRISACCHARIDES, AND PENTASACCHARIDES OF HEPARINOIDS | HPSE, DDOST, FUT5 | IARS1 2204/4885F10 134/4885 |
| US-20120220759-A1 | SYNTHETIC HEPARIN DISACCHARIDES | HPSE, DDOST, STT3A | IARS1 2424/4885F10 144/4885 |
| US-20230144378-A1 | TAFOXIPARIN FOR THE TREATMENT OF PREECLAMPSIA | PGF, PLAUR, SERPINC1 | IARS1 3846/4885F10 29/4885 |
| US-20160137754-A1 | NEW PROCESSES FOR THE PRODUCTION OF CHEMICALLY-MODIFIED HEPARINS | F10, SERPINC1, HPSE | IARS1 2741/4885F10 1/4885 |
| US-20120208993-A1 | SYNTHETIC HEPARIN TRISACCHARIDES | HPSE, SERPINC1, DDOST | IARS1 1785/4885F10 116/4885 |
| US-20110201572-A1 | PHARMACEUTICAL COMPOSITION WITH GLYCOSAMINOGLYCANS AND USE THEREOF IN THE TREATMENT OF CHRONIC ULCERS | CD44, MATR3, MMP7 | IARS1 3058/4885F10 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.